DioGenix, Fast Forward Partner on NGS-based MDx for MS | GenomeWeb

NEW YORK (GenomeWeb News) – DioGenix announced today a collaboration with Fast Forward to develop a molecular diagnostic test for multiple sclerosis.

As part of the deal, Fast Forward, a subsidiary of the National Multiple Sclerosis Society, will provide DioGenix $500,000 to expand its ongoing clinical trial for MSPrecise, a diagnostic test based on next-generation sequencing to measure genetic mutations in the adaptive immune system by analyzing B cells isolated from cerebral spinal fluid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.